A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients

Journal of the Neurological Sciences

Volumn 324, Issue 1-2, 2013, Pages 140-148

  Schneider, Jay S ^a   Gollomp, Stephen M ^a,b   Sendek, Stephanie ^a   Colcher, Amy ^c   Cambi, Franca ^d   Du, Wei ^e  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e Clinical Statistics Consulting   (United States)

Author keywords

Disease modification; Ganglioside; GM1; Parkinson's disease; Symptomatic; Treatment

Indexed keywords

GANGLIOSIDE GM1; PLACEBO;

ADULT; ARTICLE; ASTHENIA; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEMATOMA; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE URTICARIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; THERAPY DELAY; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE;

ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; G(M1) GANGLIOSIDE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84870949704     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2012.10.024     Document Type: Article

References (46)

1. M.M. Hoehn, and M.D. Yahr Parkinsonism: onset, progression and mortality Neurology 17 1967 427 442
2. R.J. Uitti, J.E. Ahlskog, and D.M. Maraganore Levodopa therapy and survival in idiopathic Parkinson's disease: Olmstead County project Neurology 43 1993 1918 1926
3. C.W. Olanow, A.H. Schapira, and Y. Agid Neuroprotection for Parkinson's disease: prospects and promises Ann Neurol 53 Suppl. 3 2003 S1 S2
4. M.L. Allende, and R.L. Proia Lubricating cell signaling pathways with gangliosides Curr Opin Struct Biol 12 2002 587 592
5. S. Hakomori, and Y. Igarashi Gangliosides and glycosphingolipids as modulators of cell growth, adhesion, and transmembrane signaling Adv Lipid Res 25 1993 147 162
6. R.W. Ledeen, and G. Wu Ganglioside function in calcium homeostatsis and signaling Neurochem Res 27 2002 637 647
7. J. Wei, M. Fujita, and M. Nakai Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies Am J Pathol 174 2009 1891 1909
8. A.J. Shield, T.P. Murray, and P.G. Board Functional characterisation of ganglioside-induced differentiation-associated protein 1 as a glutathione transferase Biochem Biophys Res Commun 347 2006 859 866
9. R. Bianchi, D. Janigro, F. Milan, G. Giudici, and A. Gorio In vivo treatment with GMI prevents the rapid decay of ATPase activity and mitochondria1damage in hippocampal slices Brain Res 364 1986 400 404
10. G. Jonsson, A. Gorio, and H. Hallman Effects of GM1 ganglioside on developing and mature serotonin and noradrenaline neurons after lesion by selective neurotoxins J Neurosci Res 12 1984 459 475
11. M. Hadjiconstantino, Z.L. Rosetti, R.C. Paxton, and N.H. Neff Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP Neuropharmacology 25 1986 1075 1077
12. H.A. Tilson, G.J. Harry, K. Nanry, P.M. Hudson, and J.S. Hong Ganglioside interactions with the dopaminergic system of rats J Neurosci Res 19 1988 88 93
13. B. Oderfeld-Nowak, M. Skup, J. Ulas, M. Jezierska, M. Gradkowska, and M. Zarenba Effect of ganglioside GM1 treatment on post-lesion responses of cholinergic enzymes in rat hippocampus after various partial deafferentations J Neurosci Res 12 1984 409 420
14. J.S. Schneider, A. Pope, K. Simpson, J. Taggart, M.G. Smith, and L. DiStefano Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment Science 256 1992 843 846
15. N.D. Stull, J.S. Schneider, and L. Iacovitti GM1 ganglioside partially rescues cultured dopaminergic neurons from MPP + induced damage: dependence on initial damage and time of treatment Brain Res 640 1994 308 315
16. A. Pope-Coleman, J.P. Tinker, and J.S. Schneider Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys Synapse 36 2000 120 128
17. M.T. Herrero, I. Perez-Otano, and C. Oset GM1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys Neuroscience 56 1993 965 972
18. J.S. Schneider, A. Kean, and L. DiStefano GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice J Neurosci Res 42 1995 117 123
19. E.E. Tseng, M.V. Brock, and M.S. Lange Monosialoganglioside GM1 inhibits neurotoxicity after hypothermic circulatory arrest Surgery 124 1998 298 306
20. H. Kojima, A. Gorio, D. Janigro, and G. Jonsson GM1 ganglioside enhances regrowth of noradrenaline nerve terminals in rat cerebral cortex lesioned by the neurotoxin 6-hydroxydopamine Neuroscience 13 1984 1011 1022
21. G.P.H. Ballough, F.J. Cann, C.D. Smith, J.S. Forster, C.E. Kling, and M.G. Filbert GM1 monosialoganglioside pretreatment protects against soman-induced seizure related brain damage Mol Chem Neuropathol 34 1998 1 23
22. J.S. Schneider, S. Sendek, C. Daskalakis, and F. Cambi GM1 ganglioside in Parkinsons disease: results of a five year open study J Neurol Sci 292 2010 45 51
23. Parkinson Study Group A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease Arch Neurol 61 2004 561 566
24. C.W. Olanow, R.A. Hauser, and J. Jankovic A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (The ADAGIO Study): rationale, design, and baseline characteristics Mov Disord 23 2008 2194 2201
25. R.B. D'Agostino Sr. The delayed-start study design N Engl J Med 361 2009 1304 1306
26. C.W. Olanow, O. Rascol, and R. Hauser A double-blind, delayed-start trial of rasagiline in Parkinson's disease N Engl J Med 361 2009 1268 1278
27. J.S. Schneider, D.P. Roeltgen, and E.L. Mancall Parkinson's disease: improved function with GM1 ganglioside treatment in a randomized placebo-controlled study Neurology 50 1998 1630 1636
28. J.S. Schneider, D.P. Roeltgen, D.S. Rothblat, J. Chapas-Crilly, L. Seraydarian, and J. Rao GM1 ganglioside treatment of Parkinson's disease: an open pilot study of safety and efficacy Neurology 45 1995 1149 1154
29. M. Kim, S.M. Gollomp, and J.S. Schneider Does a two rater system improve reliability of UPDRS motor scoring of mild Parkinson's disease patients? Mov Disord 21 Suppl.13 2006 S26
30. L. Svennerholm, C.G. Gottfries, and K. Blennow Parenteral administration of GM1 ganglioside to presenile Alzheimer patients Acta Neurol Scand 81 1990 48 53
31. L.M. Shulman, A.L. Gruber-Baldini, and K.E. Anderson The clinically important difference on the Unified Parkinson's Disease Rating Scale Arch Neurol 67 2010 64 70
32. C.L. Tomlinson, R. Stowe, S. Patel, C. Rick, R. Gray, and C.E. Clarke Systematic review of levodopa dose equivalency reporting in Parkinson's disease Mov Disord 25 2010 2649 2685
33. F.J.G. Vingerhoets, M. Schulzer, D.B. Calne, and B.J. Snow Which clinical signs of Parkinson's disease best reflect the nigrostriatal lesion? Ann Neurol 41 1997 58 64
34. L.D. Zajchowski, and S.M. Robbins Lipid rafts and little caves. Compartmentalized signaling in membrane microdomains Eur J Biochem 269 2002 737 752
35. V. Michel, and M. Bakovic Lipid rafts in health and disease Biol Cell 99 2007 129 140
36. M.S. Goldberg, and P.T. Lansbury Jr. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2 2000 E115 E119
37. Z. Martinez, M. Zhu, and S. Han GM1 specifically interacts with α-synuclein and inhibits fibrillation Biochemistry 46 2007 1868 1877
38. L. Fallon, F. Moreau, and B.G. Croft Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain J Biol Chem 277 2002 486 491
39. T. Hatano, S.-I. Kubo, and S. Imai Leucine-rich repeat kinase 2 associates with lipid rafts Hum Mol Genet 16 2007 678 690
40. A. Figueras, F.J. Morales-Olivas, D. Capella, V. Palop, and J.R. Laporte Bovine gangliosides in acute polyneuropathy BMJ 305 1992 1330 1331
41. G. Landi, R. D'Alessandro, and B.C. Dossi Guillain-Barré syndrome after exposure to gangliosides BMJ 307 1993 1463 1464
42. R. Raschetti, M. Maggini, and P. Popoli Gangliosides and Guillain-Barré syndrome J Clin Epidemiol 48 1995 1399 1405
43. I. Illa, N. Ortiz, E. Gallard, C. Juarez, J.M. Grau, and M.C. Dalakas Acute inflammatory demyelinating axonal Guillain-Barré syndrome with IgG antibodies against motor polyradiculoneuropathy Ann Neurol 38 1995 218 224
44. R.K. Yu, R.K. Saito, Y. Zhang, R. Fiorentini, F. Khin-Maung-Gyi, and G. Friday Analysis of serum anti-GM1 antibody titres in patients receiving GM1 therapy Soc Neurosci Abstr 18 1992 1472
45. V. Govoni, E. Granieri, M. Manconi, J. Capone, and I. Casetta Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy J Neurol Sci 216 2003 99 103
46. R. de la Fuente-Fernandez, M. Schulzer, E. Mak, and V. Sossi Trials of neuroprotective therapies for Parkinson's disease: problems and limitations Parkinsonism Relat Disord 16 2010 365 369